Ensysce Biosciences, Inc. ENSC

ENSC Company Overview

Ensysce Biosciences, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing tamper-resistant and abuse-deterrent prescription opioid products intended to reduce misuse, overdose, and addiction risks while maintaining pain-management efficacy. The company operates within the pharmaceutical and biotechnology industries, with a strategic emphasis on pain therapeutics, opioid safety technologies, and overdose protection systems. Its core development programs are centered on proprietary technologies designed to prevent oral and intravenous abuse of opioid medications and to mitigate accidental or intentional overdose.

The company’s primary technology platforms include TAAP (Trypsin Activated Abuse Protection) and MPAR (Multi-Pill Abuse Resistance). The TAAP platform is designed to render opioid drugs inactive unless metabolized appropriately in the gastrointestinal tract, while MPAR is intended to reduce the risk of overdose from excessive pill consumption. Ensysce’s pipeline has included product candidates based on oxycodone and hydrocodone formulations targeting chronic and acute pain markets. Originally formed through technology development efforts associated with academic research, the company evolved into a publicly traded biotechnology firm focused on safer opioid therapeutics amid increased regulatory and public-health scrutiny surrounding opioid misuse.